



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

:Confirmation No.: 3765

Gebeyehu et al.

: Group Art Unit: 1631

Serial No.: 09/326,106

: Examiner: Marschel, A.H.

Filed: June 4, 1999

For: NOVEL REAGENTS FOR
INTRACELLULAR DELIVERY OF
MACROMOLECULES

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Express Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231	
On <u>9/2/03</u>	<u>L Murray</u> Lea Murray
<u>EL 982 115 395 US</u> Express Mail Certificate Number	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Further to the Information Disclosure Statements filed in the above-referenced case on September 28, 1999 and July 11, 2000, the Examiner is respectfully requested to consider the additional references provided herewith which may be considered relevant. For the Examiner's convenience, the references are listed on the attached Patent and Trademark Office Form PTO - 1449 which has five pages.

This submission is made concurrently with the filing of a Request for Continued Prosecution in the above-referenced application in which a Final Office Action has been issued by the Examiner. This submission is made under 37 CFR 1.97 (b) 4 and as such that no fee payment is required for its submission.

References listed on pages 4 and 5 of the attached 1449 Form were submitted by Applicants in U.S. serial number 08/195,866 filed February 11, 1994, from which the above-

referenced application takes priority under 35 U.S.C. §120. It is believed unnecessary under 37 C.F.R. §1.98(a) to submit copies of these previously submitted or cited items. Copies of other references listed on the 1449 Form are submitted herewith.

Where the month of a reference is not listed, the year of the publication is believed to be sufficient to allow a determination of the difference in the effective filing date of the above-referenced application and the publication date of the reference.

The Examiner's attention is also drawn to the following commonly-owned, unpublished patent applications which may be considered to contain relevant subject matter: USSN 08/450,555, filed May 25, 1995; 09/438,365, filed November 12, 1999, USSN 09/937,837, filed January 7, 2002; USSN 10/200,879, filed July 23, 2002; and USSN 10/269,522, filed on July 28, 2003. These unpublished applications are not listed on Form 1449. USSN 09/937,837 is a national stage of WO00/58488 and believed to be identical in content to the published PCT application. A copy of 09/937,837 is not provided. USSN 10/269,522 is a continuation of USSN 09/438,365. Only a copy of USSN 09/438,365 is submitted. Copies of the remaining applications are submitted herewith.


The following published or issued U.S. patent applications listed in Form 1449 are commonly owned with the above-referenced application:: US 5,334,761, US 5,578,475, US 5,627,159, US 5,674,908, US 5,736,392, US 5,834,439, US 6,020,202, US 6,051,429, US 6,110,916, US 6,376,248, US 6,399,663, US20020077305, US20020086849; US20020156049, and US20030069173. Copies of these references are submitted herewith.

The following concise explanation of the relevance of FR 1,567,214 is provided because the document is not available in English. FR 1,567,214 relates to a detergent containing a cationic composition which is reported to be useful for washing textiles in mechanical washing machines. The relevance of the reference to the above-referenced application is believed to be further illustrated by the chemical structures shown throughout the reference.

References known to Applicants have been listed herein. That information is cited in a spirit of forthrightness and cooperation to enable the applicants to obtain that measure of protection for the invention to which there is entitlement. No representation is made that the listed art actually qualifies as prior art under the patent statute and the listed of the references in Form 1449 is not intended as an admission that the listed art is prior art. No representation is made that the applicants know of the best art.

As noted above, this submission does not require the payment of any fees. If this is incorrect, please deduct the appropriate fee from deposit account 07-1969.

Respectfully submitted,


Sally A. Sullivan
Reg. No. 32,064

GREENLEE, WINNER AND SULLIVAN, P.C.
5370 Manhattan Circle, Suite 201, Boulder, CO 80303
Telephone: (303) 499-8080;
Facsimile: (303) 499-8089
Attorney Docket No. 45-93A
SAS:lem:September 2, 2003

SEP 02 2003

Sheet 1 of 5

Form PTO-144	ATTY DOCKET NO. 45,93A		SERIAL NO. 09/326,106	FILING DATE June 4, 1999
APPLICANT Gebeyehu			GROUP	

U.S. PATENT DOCUMENTS

Exmr. Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	6,399,663	06/04/02	Haces et al.	514	642	
	6,387,395	05/14/02	Eppstein et al.	424	450	
	6,376,248	04/23/02	Hawley-Nelson et al.	435	458	
	6,214,804	04/10/01	Felgner et al.	514	44	
	6,110,916	08/29/00	Haces et al.	514	252.11	
	6,110,662	08/29/00	Foung et al.	435	5	
	6,086,913	07/11/00	Tam et al.	424	450	
	6,051,429	04/18/00	Hawley-Nelson et al.	435	458	
	6,020,202	02/01/00	Jessee	435	458	
	5,948,925	09/07/99	Keynes et al.	552	540	
	5,948,767	09/07/99	Scheule et al.	514	44	
	5,935,936	08/10/99	Fasbender et al.	514	44	
	5,908,777	06/01/99	Lee et al.	435	320	
	5,908,635	06/01/99	Thierry	424	450	
	5,906,922	05/25/99	Whittaker et al.	435	69.1	
	5,869,606	02/09/99	Whittaker	530	345	
	5,854,224	12/29/98	Lockett et al.	514	44	
	5,840,710	11/24/98	Lee et al.	514	44	
	5,834,439	11/10/98	Haces et al.	514	42	
	5,830,878	11/03/98	Gorman et al.	514	44	
	5,830,430	11/03/98	Unger et al.	424	1.21	
	5,827,703	10/27/98	Debs et al.	435	172.3	
	5,795,587	08/18/98	Gao et al.	424	450	
	5,785,992	07/28/98	Ansell et al.	424	450	
	5,783,565	07/21/98	Lee et al.	514	44	
	5,780,053	07/14/98	Ashley et al.	424	450	
	5,753,613	05/19/98	Ansell et al.	514	2	
	5,744,335	04/28/98	Wolff et al.	435	172.3	
	5,736,392	04/07/98	Hawley-Nelson et al.	435	320.1	
	5,719,131	02/17/98	Harris et al.	514	44	
	5,703,055	12/30/97	Felgner et al.	514	44	
	5,693,509	12/02/97	Cotten et al.	435	172.3	
	5,674,908	10/07/97	Haces et al.	514	642	
	5,650,096	07/22/97	Harris et al.	252	357	
	5,627,159	05/06/97	Shih et al.	514	44	
	5,595,897	01/21/97	Midoux et al.	435	172.3	
	5,589,466	12/31/96	Felgner et al.	514	44	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEP 02 2003

Sheet 2 of 5

Form PTO-1449		ATTY DOCKET NO. 45-93A		SERIAL NO. 09/326,106	FILING DATE June 4, 1999
APPLICANT Gebeyehu et al.				GROUP	

	5,583,198	12/10/96	Whittaker	530	345	
	5,578,475	07/12/94	Jessee	435	172.3	
	5,550,289	08/27/96	Eppstein et al.	564	293	
	5,545,412	08/13/96	Eppstein et al.	424	450	
	5,512,291	05/28/96	Curiel et al.	530	391.7	
	5,459,127	10/17/95	Felgner et al.	514	7	
	5,455,335	10/03/95	Kahne et al.	536	5	
	5,334,761	08/02/94	Gebeyehu et al.	564	197	
	5,283,185	02/01/94	Epand et al.	435	172.3	
	5,279,833	01/18/94	Rose	424	450	
	5,165,925	11/24/92	Leong	424	88	
	4,235,871	11/25/80	Papahadjopoulos et al.	424	19	
	3,152,188	10/06/64	Kirkpatrick et al.	260	584	
	2,901,461	08/25/59	Auerbach et al.	260	47	
	2003-0069173	04/10/03	Hawley-Nelson et al.	514	8	
	2002-0156049	10/24/02	Haces et al.	514	79	
	2002-0086849	07/04/02	Gebeyehu et al.	514	44	
	2002-0077305	06/20/02	Jessee et al.	514	44	

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes/No
WO 02/34879	05/02/02	PCT	C12N		
WO 00/27795	05/18/00	PCT	C07C 211/64		
WO 00/58488	10/05/00	PCT	C12N 15/87		
WO 99/29712	06/17/99	PCT	C07K 5/02		
WO 99/02190	01/21/99	PCT	A61K 48/00		
WO 98/40502	09/17/98	PCT	C12N 15/64		
WO 98/29541	07/09/98	PCT	C12N 15/00		
WO 98/02190	01/22/98	PCT	A61K 47/48		
WO 97/42819	11/20/97	PCT	A01N 37/18		
WO 96/40961	12/19/96	PCT	C12N 15/88		
WO 95/02698	01/26/95	PCT	C12N 15/88		
WO 95/17373	06/29/95	PCT	C07C 211/63		
WO 94/27435	12/08/94	PCT	A01N 25/26		
WO 91/17424	11/14/91	PCT	G01N 21/00		
WO 90/11092	10/04/90	PCT	A61K 48/00		
0 846 680 A1	06/10/98	EP	C07C 279/12		
1,567,214	05/16/69	FR	C11D		

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEP 02 2003

Sheet 3 of 5

Form PTO-144		
ATTY DCKET NO. 45-93A	SERIAL NO. 09/326,106	FILING DATE June 4, 1999
APPLICANT Gebeyehu		GROUP

OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, etc.)

		Behr, J-P. (Sept. 1994), "Gene Transfer with Synthetic Cationic Amphiphiles: Prospects for Gene Therapy," Bioconjug. Chem. 5:382-389
		Bottger, M. et al. (1988), "Condensation of vector DNA by the chromosomal protein HMG1 results in efficient transfection," Biochim. Biophys. Acta 950:221-228
		Cotten, M. and Wagner, E. (Dec. 1993), "Non-viral approaches to gene therapy," Curr. Opin. Biotechnol. 4:705-710
		Giles, R.V. (2000), "Antisense oligonucleotide technology: From EST to therapeutics," Curr. Opin. Mol. Therap. 2:238-252
		Henkel und Cie. G.m.b.H. (April 1970), abstract no. 68522p, "Low-foaming detergents containing bisquaternary compounds," Chem. Abst. 72(14):116
		Kaneda, Y. et al. (1989), "Increased Expression of DNA Cointroduced with Nuclear Protein in Adult Rat Liver," Science 243:375-378
		Murphy, A.L. (Jan. 1999), "Catch VP22: the hitch-hiker's ride to gene therapy?" Gene Therapy 6:4-5
		Neckers, L.M. (May 1993), "Cellular Internalization of Oligodeoxynucleotides," in Antisense Research and Applications, Crooke, S.T. and Leblue, B., eds., CRC Press, LLC, Boca Raton, FL, pp. 451-460
		Neurath, et al. (1990), "B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides," J. Gen. Virol. 71:85-95
		Rothenberg, M. et al. (1989), "Oligodeoxynucleotides as Anti-Sense Inhibitors of Gene Expression: Therapeutic Implications," J. Natl. Can. Inst. 81:1539-1544
		van der Krol, A.R. et al. (1988), "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences," Biotechniques 6:958-976
		Wixon, H.E. (1969), "Anionic detergents containing trialkylamine oxides as fabric softeners," Chem. Abstracts, Vol. 72, Abstract No. 68523q, p. 116
		(Jan. 1993) Sigma Catalog, pp. 1028-1034

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	ATTY DOCKET NO. 445-93A		SERIAL NO. 09/326,106	FILING DATE June 4, 1999
APPLICANT Gebeyehu			GROUP	

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes/No
WO 93/14778	08/05/93	PCT	A61K 37/00		
WO 93/05162	03/18/93	PCT	C12N 15/63		
WO 93/03709	03/04/93	PCT	A61K 9/127		

OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, etc.)

	Bennett, C.F. et al. (1992), "Cationic Lipids Enhance Cellular Uptake and Activity of Phosphorothioate Antisense Oligonucleotides," Mol. Pharm. 41 :1023-1033
	Bond, V.C. and Wold, B. (June 1987), "Poly-L-Ornithine-Mediated Transformation of Mammalian Cells," Mol. Cell. Biol. 7 (6):2286-2293
	Chaney, W.G. et al. (1986), "High-Frequency Transfection of CHO Cells Using Polybrene," Som. Cell Mol. Genet. 12 (3):237-244
	Dong, Y. et al. (1993), "Efficient DNA transfection of quiescent mammalian cells using poly-L-ornithine," Nucl. Acids Res. 21 :771-772
	Donnelly-Roberts, D.L. and Lentz, T.L. (1991), "Structural and conformational similarity between synthetic peptides of curare-mimetic neurotoxins and rabies virus glycoprotein," Mol. Brain Res. 11 :107-113
	Duzgunes, N. and Felgner, P. (1993), "Intracellular Delivery of Nucleic Acids and Transcription Factors by Cationic Liposomes," Meth. Enzymol. 221 :303-317
	Farhood, H. et al. (1992), "Effect of cationic cholesterol derivatives on gene transfer and protein kinase C activity," Biochim. Biophys. Acta 1111 :239-246
	Felgner, P.L. et al., "Enhanced Gene Delivery and Mechanism Studies with a Novel Series of Cationic Lipid Formulations," Genetically Targeted Research & Therapies: Antisense and Gene Therapy, S306, p. 206
	Felgner, P.L. and Holm, M. (Spring 1989), "Cationic Liposome-Mediated Transfection," Focus 11 (2):21-25
	Felgner, P.L. (1993), "Cationic Lipid/Polynucleotide Condensates for In Vitro and In Vivo Polynucleotide Delivery - The Cytofectins," J. Liposome Res. 3 (1):3-16
	Gao, X. and Huang, L. (1993), "Cationic Liposomes and Polymers for Gene Transfer," J. Liposome Res. 3 (1):17-30
	Gao, X. and Huang, L. (1993), "Cytoplasmic expression of a reporter gene by co-delivery of T7 RNA polymerase and T7 promoter sequence with cationic liposomes," Nucl. Acids Res. 21 (12):2867-2872
	Huang, L. and Zhou, F. (1992), "Liposome and Immunoliposome Mediated Delivery of Proteins and Peptides," Targeting of Drugs 3 - The Challenge of

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		
ATTY DOCKET NO. 45-93A	SERIAL NO. 09/326,106	FILING DATE June 4, 1999
APPLICANT Gebeyehu		GROUP

		Peptides and Proteins, Gregoriadis, G. and Florence, A.T. (eds.), Plenum Press, New York, NY, pp. 45-50
		Litzinger, D.C. and Huang, L. (1992), "Amphipathic poly(ethylene glycol) 5000-stabilized dioleoylphosphatidylethanolamine liposomes accumulate in spleen," Biochim. Biophys. Acta 1127 :249-254
		Litzinger, D.C. and Huang, L. (1992), "Phosphatidylethanolamine liposomes: drug delivery, gene transfer and immunodiagnostic applications," Biochim. Biophys. Acta 1113 :201-227
		Nabel, G.J. and Felgner, P.L. (May 1993), "Direct gene transfer for immunotherapy and immunization," Tibtech 11 :211-215
		Nair, S. et al. (1992), "Class I restricted CTL recognition of a soluble protein delivered by liposomes containing lipophilic polylysines," J. Immun. Meth. 152 :237-243
		Park, Y.S. and Huang, L. (1992), "Interaction of synthetic glycopospholipids with phospholipid bilayer membranes," Biochim Biophys. Acta 1112 :251-258
		Park, Y.S. et al. (1992), "Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo," Biochim. Biophys. Acta 1108 :257-260
		Stegmann, T. et al. (1989), "Protein-Mediated Membrane Fusion," Ann. Rev. Biophys. Biophys. Chem. 18 :187-211
		Stewart, M.J. et al. (1992), "Gene Transfer In Vivo with DNA-Liposome Complexes: Safety and Acute Toxicity in Mice," Human Gene Therapy 3 :267-275
		Trubetskoy, V.S. et al. (1992), "Cationic liposomes enhance targeted delivery and expression of exogenous DNA mediated by N-terminal modified poly(L-lysine)-antibody conjugate in mouse lung endothelial cells," Biochim. Biophys. Acta 1131 :311-313
		Trubetskoy, V.S. et al. (1992), "Use of N-Terminal Modified Poly(L-lysine)-Antibody Conjugate as a Carrier for Targeted Gene Delivery in Mouse Lung Endothelial Cells," Bioconjugate Chem. 3 :323-327
		White, J.M. (1989), "Cell-to-cell fusion," Cell. Biol. 1 :934-939
		White, J.M. (1990), "Viral and Cellular Membrane Fusion Proteins," Ann. Rev. Physiol. 52 :675-697
		Zhou, X. and Huang, L. (1992), "Targeted delivery of DNA by liposomes and polymers," J. Controlled Release 19 :269-74

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.